NCT03819387View on ClinicalTrials.gov

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

November 2, 2023

Study Completion Date

March 12, 2024

Conditions
Non-Small Cell Lung CancerPancreatic CancerColorectal Cancer
Interventions
DRUG

NBF-006

Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks

Trial Locations (9)

22031

NEXT Oncology - Virginia, Fairfax

33612

Moffitt Cancer Center, Tampa

37203

Vanderbilt-Ingram Cancer Center, Nashville

43614

University of Toledo, Eleanor N. Dana Cancer Center, Toledo

75230

Mary Crowley Cancer Research Center, Dallas

78240

NEXT Oncology - San Antonio, San Antonio

78758

NEXT Oncology - Austin, Austin

90211

Beverly Hills Cancer Center, Beverly Hills

92093

UC San Diego Moores Cancer Center, La Jolla

Sponsors
All Listed Sponsors
lead

Nitto BioPharma, Inc.

INDUSTRY

NCT03819387 - A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer | Biotech Hunter | Biotech Hunter